Insiders Trades
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (31 ops.)
Latest filing published 09 Dec 2025 for Akero Therapeutics, Inc.. Read the official filing
Filing timeline
BuySaleAndrew Cheng
Insider track record
Disclosed buys
0
Disclosed sells
31
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Andrew Cheng: trading record in brief
Andrew Cheng is a declared insider at 2 companies (chief executive); the most frequent names are Akero Therapeutics, Inc. and Vera Therapeutics, Inc. In total, 75 filings cover trades dated from 18 May 2021 to 9 December 2025.
On the market, this insider has only sold: 31 sales, €15.4M in total. Outside the open market, there are 6 share grants and 33 option exercises. In 2025 alone, the filings show no purchases and 16 sales.
Most recently, on 9 December 2025, the filings show a transaction in Akero Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Andrew Cheng
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations75 total
277,075 sharesCommon StockSEC:0001193125-25-312131:0
159,762 sharesCommon StockSEC:0001193125-25-312131:1
74,538 shares0Common StockSEC:0001193125-25-291688:0
14,739 shares0Common StockSEC:0001193125-25-280748:0
30,000 shares@ US$19.872.5% of flowCommon StockSEC:0001193125-25-239343:0
30,000 shares@ US$53.9786.7% of flowCommon StockSEC:0001193125-25-239343:1
52,212 shares@ US$0.6150.1% of flowCommon StockSEC:0001193125-25-236151:0
13,022 shares@ US$6.3640.3% of flowCommon StockSEC:0000950170-25-114661:0
10,795 shares@ US$48.072.1% of flowCommon StockSEC:0000950170-25-108232:0
14,686 shares@ US$50.573.1% of flowCommon StockSEC:0000950170-25-095409:0
890 shares@ US$23.8680.1% of flowCommon StockSEC:0000950170-25-093316:0
6,620 shares@ US$54.841.6% of flowCommon StockSEC:0000950170-25-088641:0
14,842 shares@ US$53.763.6% of flowCommon StockSEC:0000950170-25-085674:0
7,200 shares@ US$41.001.3% of flowCommon StockSEC:0000950170-25-070811:0
22,800 shares@ US$41.6344.1% of flowCommon StockSEC:0000950170-25-070811:1
30,000 shares@ US$35.2264.5% of flowCommon StockSEC:0000950170-25-053391:0
1,738 shares@ US$44.880.3% of flowCommon StockSEC:0000950170-25-039765:0
28,784 shares@ US$41.7465.3% of flowCommon StockSEC:0000950170-25-038177:0
6,439 shares@ US$52.9081.6% of flowCommon StockSEC:0000950170-25-018311:1
749 shares@ US$54.5460.2% of flowCommon StockSEC:0000950170-25-018311:3
12,640 shares@ US$51.7523.1% of flowCommon StockSEC:0000950170-25-018311:0
9,972 shares@ US$53.6662.5% of flowCommon StockSEC:0000950170-25-018311:2
200 shares@ US$55.810.1% of flowCommon StockSEC:0000950170-25-018311:4
24,242 shares@ US$54.566.1% of flowCommon StockSEC:0000950170-25-010705:0
50,000 shares@ US$0.6150.1% of flowCommon StockSEC:0000950170-25-009324:0
25 of 75 declarations
